Interleukin-1α neutralisation in patients with cancer

The Lancet Oncology

Volumn 15, Issue 6, 2014, Pages 552-553

  Dinarello, Charles Anthony ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MONOCLONAL ANTIBODY P1; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NOTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; MALE; NEOPLASMS;

EID: 84899980380     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70164-0     Document Type: Note

References (10)

1. Dinarello CA, Simon A, van der Meer JW Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
2. Balkwill FR, Mantovani A Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012, 22:33-40.
3. Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 2014, published online April 17. http://dx.doi.org/10.1016/S1470-2045(14)70155-X.
4. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009, 84:114-122.
5. Dinarello CA Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev 2010, 29:317-329.
6. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med 1983, 308:553-558.
7. Smith JW, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993, 328:756-761.
8. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993, 81:2492-2495.
9. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645-2650.
10. Smith CJ, Emsley HC, Udeh CT, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 2012, 58:384-389.